Clinical trials: Liver Tumour
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
- Trial name
- NCT05775159
- Testing
- Volrustomig, Bevacizumab, Lenvatinib
- Where
- 46 sites in United States, China and 7 more
- Volunteers
- 294 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma
The primary objective of this study is to answer the question "Is it possible to inject the COMBIG-DC vaccine in a hepatic tumor without getting unacceptable side effects"?
- Trial name
- NCT01974661
- Testing
- COMBIG-DC (ilixadencel)
- Where
- Sweden
- Volunteers
- 18 people
- Sponsor
- Mendus
Liver Tumors, HCC - Hepatocellular Carcinoma
Needle-based Percutaneous Ablation of Liver Tumors.
The goal of this clinical trial is to learn if INT001 can ablate liver tumors in adults in an outpatient setting. It will also help us learn about the safety of INT001. The main questions it aims to answer are: 1.
- Conditions
- Liver Tumors, HCC - Hepatocellular Carcinoma, Metastatic Liver Tumor
- Trial name
- NCT06689670
- Testing
- Needle based delivery of INT001 into liver tumors under real-time image guidance
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- inTumo Therapeutics, Inc.
Hepatocellular Carcinoma
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma
The purpose of the study is to determine whether interferon-alpha is effective in the treatment of p48 Positive patients with HCC after curative resection.
- Trial name
- NCT00838968
- Testing
- interferon-alpha
- Sponsor
- Fudan University
Colorectal Cancer, Metastatic Liver Cancer
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Recurrence of liver metastasis in colorectal cancer after R0 resection is mainly due to the invisible minimal residual disease, which are the main factors leading to metastasis and recurrence.
- Trial name
- NCT05240950
- Testing
- Anti-CEA CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
Colorectal Cancer, Coffee
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery…
- Conditions
- Colorectal Cancer, Coffee, Gastrointestinal Microbiome, Stenosis
- Trial name
- COMMENCER (NCT05692024)
- Testing
- Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma
Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)
The purpose of this study is to evaluate the efficacy and safety of apatinib in patients with advanced HCC.
- Trial name
- HCC (NCT03046979)
- Testing
- Apatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC - Hepatocellular Carcinoma
A Prospective Observational Cohort Study on Dynamic CD8+ T-cell Profiling and Multi-omics Biomarkers for Predicting Conversion Therapy Response in Unresectable Hepatocellular Carcinoma
This study aims to identify early predictors for successful liver cancer treatment conversion. We will track changes in immune cells (CD8+ T-cells) in the blood during chemotherapy infusion (HAIC/TACE) combined with…
- Trial name
- NCT07117279
- Volunteers
- 120 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
This study will evaluate efficacy and safety of Toripalimab Injection (JS001) with or without Lenvatinib as a Neoadjuvant Therapy in patients with Resectable Hepatocellular Carcinoma (HCC)
- Trial name
- NCT03867370
- Testing
- Toripalimab (JS001 ), Toripalimab (JS001 ) Lenvatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Hepatocellular Carcinoma, Esophageal Cancer
PLA for HCC and Esophageal ca Serum
The primary goal of this study is to quantify the biomarkers of pre-radiation therapy(RT), during-RT, and post-RT serum samples from hepatocellular carcinoma (HCC) and esophageal cancer patients undergoing definitive or…
- Trial name
- NCT01957241
- Where
- Taiwan
- Volunteers
- 164 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Hepatocellular
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of Serplulimab Injection (HLX10, a Recombinant Anti-PD-1 Antibody) and HLX04 (a Biosimilar to Bevacizumab) With…
- Trial name
- NCT06349980
- Testing
- HLX53 (1000mg), HLX53 (2000mg), HLX10
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Shanghai Henlius Biotech
Carcinoma, Hepatocellular
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer.
- Trial name
- NCT00699374
- Testing
- sunitinib malate, sorafenib
- Where
- 171 sites in United States, Australia and 21 more
- Volunteers
- 1,075 people
- Sponsor
- Pfizer
Hepatic Insufficiency, Liver Diseases
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.
- Trial name
- NCT07559474
- Testing
- INCB123667
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Uveal Melanoma
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
This study seeks to better understand the liver's immune response to receiving chemotherapy agent melphalan through Percutaneous Hepatic Perfusion (PHP) alone or in combination with Ipilimumab and Nivolumab for patients with…
- Trial name
- NCT07364474
- Testing
- Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
The primary purpose of this study is to demonstrate the safety and effectiveness of using an intra-operative ultrasound contrast agent(Definity®) for the identification of known liver tumors.
- Trial name
- Definity® (NCT00955097)
- Testing
- Definity®
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Louisville
Liver Neoplasms, Liver/Hepatobiliary Cancer
CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases
Contrast-enhanced intraoperative ultrasound (CE-IOUS) plays an increasingly important role in the surgical therapy planning of primary liver lesions as well as liver metastases.
- Conditions
- Liver Neoplasms, Liver/Hepatobiliary Cancer, Colorectal Cancer Metastatic, Metastases
- Trial name
- NCT05261113
- Testing
- CE-IOUS
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Regensburg
Hepatocellular Carcinoma
RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of cancer-related death worldwide. Recurrence of tumor within the liver remnant is common, with a reported 5-year recurrence rate of 70%.
- Trial name
- NCT02678013
- Testing
- RFA, RFA+highly-purified CTL
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Ming Kuang
Regional Anesthesia, Pain Control
CMRA for US-guided-MWA of Liver Tumors
Patients with liver tumors who underwent US-guided-MWA of liver tumors were enrolled. These patients were allocated into three groups based on tumor size and number: A, B, and C.
- Conditions
- Regional Anesthesia, Pain Control, Microwave Ablation, Liver Tumors
- Trial name
- NCT05990257
- Testing
- HHB+TAPB+and LA, HHB+LA, TAPB+LA
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Lu Wang
Melanoma, Ocular, Melanoma, Cutaneous
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
The primary purpose of this study is to determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (ipilimumab and nivolumab) in adults with metastatic melanoma with…
- Conditions
- Melanoma, Ocular, Melanoma, Cutaneous, Metastatic Melanoma, Melanoma, Mucosal
- Trial name
- NCT05169957
- Testing
- Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Michigan Rogel Cancer Center
Liver Cancer, Post Ablation Syndrome
The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation
Background: This study aims to test whether 5% lidocaine patches can reduce Radiofrequency ablation-induced pain. Methods: The study will enroll patients with hepatocellular carcinoma and schedule a radiofrequency ablation…
- Trial name
- NCT05732181
- Testing
- The skin lidocaine patch.
- Where
- Taiwan
- Volunteers
- 154 people
- Sponsor
- National Cheng-Kung University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.